Protocols for Studies on Genetically Engineered Mouse Models in Prostate Cancer

Research output: Chapter in Book/Report/Conference proceedingChapter (peer-reviewed)

Abstract

Cancer studies have entered an era that is heavily focused on the contribution of the tumor microenvironment. For this reason, in vivo experimentation in an immunodeficient model system is no longer fit for purpose. As a consequence, numerous genetically engineered mouse models (GEMMs) which self-develop tumors have been developed to allow experiments to be performed in a fully immunocompetent setting. One of the most commonly used technologies is Cre-loxP recombination due to its unique ability to control target gene expression in a specified tissue type. However, the major limitation of these models remains the inability to generate sufficient numbers of age-matched mice for a synchronized experimental start date. For this reason, the derivation of cell lines from genetically modified murine prostate tissue is desirable and allows for the generation of syngeneic models via subcutaneous or orthotopic injection.
Original languageEnglish
Title of host publicationProstate Cancer Methods and Protocols
PublisherHumana Press
Chapter11
Pages195-206
Volume1786
DOIs
Publication statusPublished - 2018

Fingerprint

Prostatic Neoplasms
Tumor Microenvironment
Genetic Recombination
Prostate
Neoplasms
Technology
Gene Expression
Cell Line
Injections

Cite this

Armstrong, C. (2018). Protocols for Studies on Genetically Engineered Mouse Models in Prostate Cancer. In Prostate Cancer Methods and Protocols (Vol. 1786, pp. 195-206). Humana Press. https://doi.org/10.1007/978-1-4939-7845-8_11
Armstrong, Chris. / Protocols for Studies on Genetically Engineered Mouse Models in Prostate Cancer. Prostate Cancer Methods and Protocols. Vol. 1786 Humana Press, 2018. pp. 195-206
@inbook{f9bd7f33c8ed4ac099ead8f26277c0fe,
title = "Protocols for Studies on Genetically Engineered Mouse Models in Prostate Cancer",
abstract = "Cancer studies have entered an era that is heavily focused on the contribution of the tumor microenvironment. For this reason, in vivo experimentation in an immunodeficient model system is no longer fit for purpose. As a consequence, numerous genetically engineered mouse models (GEMMs) which self-develop tumors have been developed to allow experiments to be performed in a fully immunocompetent setting. One of the most commonly used technologies is Cre-loxP recombination due to its unique ability to control target gene expression in a specified tissue type. However, the major limitation of these models remains the inability to generate sufficient numbers of age-matched mice for a synchronized experimental start date. For this reason, the derivation of cell lines from genetically modified murine prostate tissue is desirable and allows for the generation of syngeneic models via subcutaneous or orthotopic injection.",
author = "Chris Armstrong",
year = "2018",
doi = "10.1007/978-1-4939-7845-8_11",
language = "English",
volume = "1786",
pages = "195--206",
booktitle = "Prostate Cancer Methods and Protocols",
publisher = "Humana Press",

}

Protocols for Studies on Genetically Engineered Mouse Models in Prostate Cancer. / Armstrong, Chris.

Prostate Cancer Methods and Protocols. Vol. 1786 Humana Press, 2018. p. 195-206.

Research output: Chapter in Book/Report/Conference proceedingChapter (peer-reviewed)

TY - CHAP

T1 - Protocols for Studies on Genetically Engineered Mouse Models in Prostate Cancer

AU - Armstrong, Chris

PY - 2018

Y1 - 2018

N2 - Cancer studies have entered an era that is heavily focused on the contribution of the tumor microenvironment. For this reason, in vivo experimentation in an immunodeficient model system is no longer fit for purpose. As a consequence, numerous genetically engineered mouse models (GEMMs) which self-develop tumors have been developed to allow experiments to be performed in a fully immunocompetent setting. One of the most commonly used technologies is Cre-loxP recombination due to its unique ability to control target gene expression in a specified tissue type. However, the major limitation of these models remains the inability to generate sufficient numbers of age-matched mice for a synchronized experimental start date. For this reason, the derivation of cell lines from genetically modified murine prostate tissue is desirable and allows for the generation of syngeneic models via subcutaneous or orthotopic injection.

AB - Cancer studies have entered an era that is heavily focused on the contribution of the tumor microenvironment. For this reason, in vivo experimentation in an immunodeficient model system is no longer fit for purpose. As a consequence, numerous genetically engineered mouse models (GEMMs) which self-develop tumors have been developed to allow experiments to be performed in a fully immunocompetent setting. One of the most commonly used technologies is Cre-loxP recombination due to its unique ability to control target gene expression in a specified tissue type. However, the major limitation of these models remains the inability to generate sufficient numbers of age-matched mice for a synchronized experimental start date. For this reason, the derivation of cell lines from genetically modified murine prostate tissue is desirable and allows for the generation of syngeneic models via subcutaneous or orthotopic injection.

U2 - 10.1007/978-1-4939-7845-8_11

DO - 10.1007/978-1-4939-7845-8_11

M3 - Chapter (peer-reviewed)

VL - 1786

SP - 195

EP - 206

BT - Prostate Cancer Methods and Protocols

PB - Humana Press

ER -